Drug Type Antibody fusion proteins |
Synonyms- |
Target |
Action antagonists |
Mechanism FGFR1 antagonists(Fibroblast growth factor receptor 1 antagonists), FGFR4 antagonists(Fibroblast growth factor receptor 4 antagonists), GLP-1R antagonists(Glucagon-like peptide 1 receptor antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Metabolic dysfunction-associated steatotic liver disease | Preclinical | United States | 10 May 2024 |